 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Celltrion Group announced on the 2nd that it will sell its "Primary Care" business rights acquired from Takeda Pharmaceutical, a multinational pharmaceutical company, excluding domestic specialty drugs.
The sale of the Primary Care business rights will be divided into Asia-Pacific medicine (ETC) and Asia-Pacific medicine (OTC), respectively.
Among them, the ETC business right contract was signed first. The sale process is planned to be completed by March this year. The business rights will be sold to CBC Group, a Singaporean private equity fund. The sale amount is 209.9 billion won. CBC Group will establish an overseas special purpose company (SPC) and proceed with the acquisition.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
